Substantial inhibitors of SHP-1 phosphatase activity have been developed and are undergoing preclinical and clinical studies at present, including NSC-87877, sodium stibogluconate (SSG), tyrosine phosphatase inhibitor 1, and suramin, but only a few have shown antitumor activity in experimental tumor models [93]. Here, NR0B2 is linked to neoplasm.